IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia

This is an open-label, single-arm clinical study designed to evaluate the efficacy and safety of IL-5 CAR-T cell therapy in the treatment of patients with CD125-positive eosinophilic leukemia.

Trial Details

NCT ID
NCT07257640
Phase
PHASE1
Sponsor
Zhejiang University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • IL-5 CAR-T cells
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Male or female patients aged ≥18 years;
  • Diagnosis of eosinophilic leukemia (EL) established according to the WHO 2022 diagnostic criteria;
  • Interleukin-5 receptor α (IL-5Rα, CD125) is expressed on ≥50% of leukemic blasts.
  • Meet any of the following criteria for refractory/relapsed eosinophilic leukemia:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →